Compare Badger Meter Inc (BMI) vs GSK plc (GSK) Price & Performance

Badger Meter (BMI) trades at $134.77, down 1.22% amid bearish technical signals and mixed quarterly results. The stock shows strong profitability with 14.27% net margins and 18.48% ROE, though valuation appears elevated with a P/E of 31.78. Recent news highlights multiple class-action lawsuits filed against the company, creating investor uncertainty despite insider buying activity and institutional position increases.

BMI faces near-term headwinds from legal challenges and earnings misses, but maintains solid fundamentals and analyst consensus target of $155.20 suggests 15% upside potential. The key risk remains resolution of securities litigation, while the company's strong cash flow generation and market position in water technology provide long-term stability.

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.